Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease - Roberts, Andrew W.; Seymour, John F.; Brown, Jennifer R.; Wierda, William G.; Kipps, Thomas J.; Khaw, Seong Lin; Carney, Dennis A.; He, Simon Z.; Huang, David C.S.; Xiong, Hao; Cui, Yue; Busman, Todd A.; et al. (Journal of clinical oncology, 2012)
Keywords: Administration, Oral; Aged; Aniline Compounds - administration & dosage; Aniline Compounds - adverse effects; Aniline Compounds - pharmacokinetics; Aniline Compounds - pharmacology; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Apoptosis Regulatory Proteins - metabolism; Bcl-2-Like Protein 11; Biological and medical sciences; Biomarkers, Tumor - metabolism; Chromosome Deletion; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Hematologic and hematopoietic diseases; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - metabolism; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Membrane Proteins - metabolism; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; ORIGINAL REPORTS; Proto-Oncogene Proteins - metabolism; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors; Proto-Oncogene Proteins c-bcl-2 - metabolism; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Sulfonamides - pharmacology; Thrombocytopenia - chemically induced; Treatment Outcome; Tumors; Human; Relapse; Treatment resistance; Malignant hemopathy; Chronic lymphocytic leukemia; Cancerology; Treatment; Lymphoproliferative syndrome; C-Onc gene; Phase I trial; Inhibitor; Protooncogene; Cancer